Arca Biopharma Inc  

(Public, NASDAQ:ABIO)   Watch this stock  
Find more results for ABIO
0.769
+0.009 (1.18%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.74 - 0.80
52 week 0.64 - 2.00
Open 0.76
Vol / Avg. 58,212.00/451,887.00
Mkt cap 16.30M
P/E     -
Div/yield     -
EPS -0.47
Shares 21.20M
Beta 2.19
Inst. own 19%
Jan 12, 2015
ARCA Biopharma Inc at OneMedForum SF
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.30% -58.34%
Return on average equity -65.58% -63.91%
Employees 16 -
CDP Score - -

Address

SUITE 140, 11080 CIRCLEPOINT ROAD
WESTMINSTER, CO 80020
United States - Map
+1-720-9402200 (Phone)
+1-720-2089261 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company�s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company�s lead product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of atrial fibrillation (AF) in patients with heart failure and/or left ventricular dysfunction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The active pharmaceutical ingredient (API) in Gencaro, bucindolol hydrochloride, has been tested clinically in approximately 4,500 patients. Gencaro was the subject of a Phase III HF mortality trial of over 2,700 patients, mostly in the United States.

Officers and directors

Robert E. Conway Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Michael R. Bristow Ph.D, M.D President, Chief Executive Officer, Director
Age: 69
Bio & Compensation  - Reuters
Thomas A. Keuer Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Christopher David Ozeroff Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Brian L Selby Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Linda S. Grais M.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Daniel J. Mitchell Director
Age: 57
Bio & Compensation  - Reuters
Raymond L. Woosley M.D., Ph.D. Director
Age: 71
Bio & Compensation  - Reuters